| Basics |
Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics Inc is a biopharmaceutical company in the United States. Its lead pipeline candidate, LN-144, uses the tumor-infiltrating lymphocytes to treat serious diseases.
|
| IPO Date: |
October 23, 2013 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$839.5M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.46 | 3.16%
|
| Avg Daily Range (30 D): |
$0.06 | 2.58%
|
| Avg Daily Range (90 D): |
$0.09 | 3.96%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
3.56M |
| Avg Daily Volume (30 D): |
9.86M |
| Avg Daily Volume (90 D): |
13.64M |
| Trade Size |
| Avg Trade Size (Sh.): |
167 |
| Avg Trade Size (Sh.) (30 D): |
358 |
| Avg Trade Size (Sh.) (90 D): |
404 |
| Institutional Trades |
| Total Inst.Trades: |
5,291 |
| Avg Inst. Trade: |
$2.55M |
| Avg Inst. Trade (30 D): |
$1.61M |
| Avg Inst. Trade (90 D): |
$1.43M |
| Avg Inst. Trade Volume: |
.22M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$3.97M |
| Avg Closing Trade (30 D): |
$1.54M |
| Avg Closing Trade (90 D): |
$1.51M |
| Avg Closing Volume: |
369.22K |
|
|
| Financials |
| |
TTM |
Q2 2025 |
Q1 2025 |
|
Basic EPS
|
|
$-.33
|
$-.36
|
|
Diluted EPS
|
|
$-.33
|
$-.36
|
|
Revenue
|
$
|
$ 59.95M
|
$ 49.32M
|
|
Gross Profit
|
$
|
$ 3.29M
|
$ -.42M
|
|
Net Income / Loss
|
$
|
$ -111.66M
|
$ -116.16M
|
|
Operating Income / Loss
|
$
|
$ -113.77M
|
$ -121.22M
|
|
Cost of Revenue
|
$
|
$ 56.66M
|
$ 49.74M
|
|
Net Cash Flow
|
$
|
$ -39.64M
|
$ 56M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Sep 26, 2013:
1:100
|
|
Apr 06, 2010:
24:1
|
|
|
|
